OTC Head Lice Treatments Are Losing Effectiveness

This article originally appeared here.
Share this content:
OTC Head Lice Treatments Are Losing Effectiveness
OTC Head Lice Treatments Are Losing Effectiveness

FRIDAY, Sept. 9, 2016 (HealthDay News) -- Over-the-counter products have lost much of their effectiveness against head lice, according to research published in the September/October issue of Pediatric Dermatology.

Ellen Koch, M.D., a dermatologist with the University of Pittsburgh Medical Center, and colleagues examined hundreds of studies regarding head lice from 1985 to 2014. According to the findings, pyrethrins and permethrin have drastically lost effectiveness. Recent research in the United States has estimated their effectiveness level at 25 percent when combined with combing of nits. That level is no better than a placebo, according to the study.

The report also warns about the use of a prescription product called lindane, due to potential toxicity. And, the researchers said there's no evidence to support the home remedies of olive oil, mayonnaise, or petroleum jelly. There's also no evidence supporting the use of essential oils, such as tea tree oils, and there's also no safety data on these treatments, the study authors added. The report supports several prescription products: ivermectin (Sklice or Stromectol), malathion (Ovide), spinosad (Natroba) and benzyl alcohol (Ulesfia).

"The availability of proven and safe prescription remedies offers the opportunity to manage head louse infestations strategically and effectively," the authors write. "Given the current situation of resistance and apparent inefficacy of over-the-counter treatments, primary health care providers should understand how to manage head lice infestations, take an active role in the diagnosis of infections, and guide appropriate use of well-tested, proven, U.S. Food and Drug Administration-reviewed products."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »